Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2024-10-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds for cash management. It details the amounts invested, types of financial products, expected and actual returns, risk control measures, and account information. The document is a progress update on the use of raised funds for cash management, not a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It is also not a regulatory certification or a voting result announcement. The document is a specific update on capital management activities related to fundraising proceeds, which fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about financing activities, not just a brief notice or report publication announcement.
2024-10-25 Chinese
金陵药业股份有限公司2024年第四次独立董事专门会议的审查意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding specific transaction proposals to be submitted to the board of directors. It references compliance with company law, securities law, and stock exchange regulations, and discusses fairness and procedural correctness of the transaction. The document is not a full financial report, earnings release, or regulatory filing but rather a specialized review or opinion related to board matters and governance. It does not contain financial statements or detailed financial data but focuses on governance and board-level review of transactions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board or senior management matters including opinions and approvals related to board meetings and transactions.
2024-10-21 Chinese
江苏泰和律师事务所关于金陵药业股份有限公司收购南京新工医疗产业投资基金合伙企业（有限合伙）部分基金份额及基金非现金分配股权暨关联交易的法律意见书
Regulatory Filings
2024-10-21 Chinese
南京新工投资集团有限责任公司拟向金陵药业股份有限公司转让持有的南京新工医疗产业投资基金合伙企业(有限合伙)部分基金份额项目资产评估报告
Regulatory Filings
2024-10-21 Chinese
金陵药业股份有限公司关于收购新工基金部分份额及新工基金非现金分配股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a corporate transaction involving the acquisition of fund shares and non-cash equity distribution related to an affiliated transaction. It includes extensive information about the parties involved, the background, the transaction details, pricing policies, agreements, and the impact on the company. The document references regulatory compliance with Shenzhen Stock Exchange listing rules and includes financial data and audit references. It is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is not a call transcript, earnings release, or management report. The content focuses on a significant capital transaction involving acquisition of fund shares and equity restructuring, which fits the category of Capital/Financing Update (CAP).
2024-10-21 Chinese
金陵药业股份有限公司关于召开2024年第四次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2024 fourth extraordinary general meeting of shareholders for Jinling Pharmaceutical Co., Ltd. It includes details about the meeting date, voting procedures, agenda items, and proxy forms. There is no financial data, earnings information, or report content. The document is an announcement informing shareholders about the meeting and how to participate, which fits the definition of AGM Information (AGM-R). The document length is 4081 characters, which is consistent with a meeting notice rather than a full report.
2024-10-21 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.